症狀性神經源性姿勢性低血壓（nOH）：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 德國 SnOH 市場預計將從 2025 年的 900 萬美元成長到 2035 年的 1,100 萬美元，這反映出與患者數量小規模且穩定相稱的逐步成長。
• 市場擴張受限的主要原因如下：
• 現有治療方法（如Midodrine和屈昔多巴）的採用正在逐步推進。
• 診斷和治療率逐步提高
• 該市場仍受到疾病認知度低、診斷延遲和治療方案缺乏創新等因素的限制。
• 未來的成長取決於提高對疾病的認知，並開發更有效的治療方法，以控制症狀並解決潛在的自主神經功能障礙。

症狀性神經源性姿勢性低血壓（nOH）概述

症狀性神經源性姿勢性低血壓（nOH）是一種使人衰弱的疾病，其特徵是血壓調節受損，由站立時交感神經釋放去甲腎上腺素受損引起。這種情況可能由神經退化α-突觸核蛋白疾病（如帕金森氏症或多重系統退化症症）或周邊神經病變所引起。從病理生理學角度來看，它涉及壓力感受器反射介導的神經病變功能障礙，導致站立後3分鐘內收縮壓持續下降20 mmHg或更多，或舒張壓持續下降10 mmHg或更多。它與非神經源性體位性低血壓的差異在於，前者心率補償增幅減弱（低於15次/分鐘）。症狀包括站立時頭暈、暈厥前兆和認知障礙，這些症狀會顯著增加跌倒的風險。診斷包括站立時的生命徵象測量、傾斜試驗和血漿兒茶酚胺水平測定。非藥物治療，例如穿戴壓力衣和補充鹽分及液體，是基本治療方法。藥物治療包括Midodrine和屈昔多巴，通常與ludrocortisone合併使用。到2026年，吡啶斯的明和阿托莫西汀將被積極納入治療方案，以最佳化姿勢性高血壓，同時避免加重仰臥位高血壓。仰臥位高血壓是併發症，需要謹慎的臨床平衡。

主要亮點

• 在法國，中度至重度 SnOH 病例數預計將從 2025 年的 11,000 例增加到 2035 年的 11,200 例，增幅非常小（年複合成長率為 0.2%），反映出患者群體相對穩定。
• 症狀持續存在且對現有治療方法反應不完全，凸顯了對更有效、更持久的治療方案的持續迫切需求。
• 尤其是在老年人群體和神經退化性疾病中，預計隨著人們意識的提高和診斷技術的進步，將能夠更逐步地識別出患者。

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

• CuraSen Therapeutics
• Theravance Biopharma

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並正在接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要治療方法－概述及關鍵意見領袖見解
• 新興治療方法
• 重點
• 值得關注的後期新興治療方法—概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 尚未滿足的主要需求及其透過新興治療方法。
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Symptomatic Neurogenic Orthostatic Hypotension (nOH) Market Outlook

Thelansis's "Global Symptomatic Neurogenic Orthostatic Hypotension (nOH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Symptomatic Neurogenic Orthostatic Hypotension treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Symptomatic Neurogenic Orthostatic Hypotension (nOH) Overview

Symptomatic neurogenic orthostatic hypotension (nOH) is a debilitating disorder of blood pressure regulation caused by impaired sympathetic release of norepinephrine upon standing. It arises from neurodegenerative alpha-synucleinopathies like Parkinson's disease and multiple system atrophy, or peripheral neuropathies. Pathophysiology involves the failure of baroreflex-mediated vasoconstriction, producing a sustained postural drop in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within three minutes of standing. It is differentiated from non-neurogenic orthostatic hypotension by a blunted compensatory heart rate increase of less than 15 beats per minute. Symptoms include standing lightheadedness, presyncope, and cognitive fog, which drive severe fall risks. Diagnosis combines orthostatic vitals, tilt-table testing, and plasma catecholamine assays. Non-pharmacological measures like compression garments and salt/fluid loading are foundational. Pharmacotherapy utilizes midodrine and droxidopa, supplemented by fludrocortisone. In 2026, protocols actively incorporate pyridostigmine or atomoxetine to optimize upright pressure without exacerbating supine hypertension, a frequent nocturnal complication requiring careful clinical balance.

Key Highlights

• In France, moderate-to-severe SnOH cases are projected to increase from 11.0K in 2025 to 11.2K by 2035, reflecting minimal growth (0.2% CAGR) and a relatively stable patient population.
• Persistent symptoms and incomplete response to existing therapies highlight a continued unmet need for more effective and durable treatment options.
• Increasing awareness and improved diagnosis, particularly in aging populations and neurodegenerative conditions, are expected to support gradual patient identification.

Market Overview

• The Germany SnOH market is projected to grow from $9M in 2025 to $11M by 2035, reflecting modest growth in line with a small and stable patient population.
• Limited market expansion is primarily driven by:
• Incremental uptake of existing therapies (e.g., midodrine, droxidopa)
• Gradual improvements in diagnosis and treatment rates
• The market remains constrained by low disease awareness, underdiagnosis, and limited innovation in therapeutic options.
• Future growth will depend on improved disease recognition and the development of more effective therapies addressing both symptomatic control and underlying autonomic dysfunction.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• CuraSen Therapeutics
• Theravance Biopharma

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)